IO Biotech, Inc.
IOBT
$0.64
$0.011.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -13.88% | 4.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.47% | 2.59% | |||
| Operating Income | 16.47% | -2.59% | |||
| Income Before Tax | 61.52% | -17.17% | |||
| Income Tax Expenses | -1,510.17% | -19.18% | |||
| Earnings from Continuing Operations | 68.04% | -16.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 68.04% | -16.93% | |||
| EBIT | 16.47% | -2.59% | |||
| EBITDA | 16.50% | -2.59% | |||
| EPS Basic | 68.53% | -16.93% | |||
| Normalized Basic EPS | 62.12% | -17.18% | |||
| EPS Diluted | 68.53% | -16.93% | |||
| Normalized Diluted EPS | 62.12% | -17.18% | |||
| Average Basic Shares Outstanding | 1.61% | 0.00% | |||
| Average Diluted Shares Outstanding | 1.61% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||